Daiichi Sankyo is bringing a seventh antibody-drug conjugate, or ADC, into its pipeline through a licensing agreement with German biotech Glycotope. Specific financials weren’t disclosed, …
This $20 million 6,000 square meter facility will be operational in 2019 and provide integrated solutions from concept to commercialization for biologics conjugates including Antibody-Drug …
